Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 5, Issue 4, Pages 601-606Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.5.4.601
Keywords
antibody; certolizumab; Crohn's disease; cytokine; immunotherapy; inflammatory arthritis; rheumatoid arthritis; therapy; TNF-alpha
Ask authors/readers for more resources
The development of biological anti-TNF-alpha therapy has revolutionised the treatment of rheumatoid arthritis and other inflammatory diseases, and has identified a worldwide market for expensive yet effective therapies for chronic diseases. Certolizumab (CDP-870) is a new agent that employs a novel strategy to neutralise TNF-alpha - namely the prokaryotic expression of TNF-alpha-specific Fab antibody fragments, coupled to polyethylene glycol - to produce a drug that is potentially less expensive to manufacture than other anti-TNF-alpha agents and which may be administered by subcutaneous injection once a month. The background to the ongoing development of this new agent and its clinical effects are discussed in this article.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available